Zhai Jinyi, Mantaj Julia, Vllasaliu Driton
School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London SE1 9NH, UK.
Pharmaceutics. 2018 Oct 15;10(4):188. doi: 10.3390/pharmaceutics10040188.
Biologics have changed the management of inflammatory bowel disease (IBD), but there are concerns with unexpected systemic toxicity and loss of therapeutic response following administration by injection. Rectal administration of biologics offers potentially reduced therapy costs, as well as safer and more effective local delivery to inflammation sites. Hydrogels are potentially useful carriers of biologics for improved delivery to the inflamed intestinal mucosa. Here, we prepared a hydrogel system based on ascorbyl palmitate (AP) and incorporated a model macromolecular drug (fluorescently-labelled dextran) into the system. Characterization of gel properties included rheology, drug loading and release, cytotoxicity, and drug delivery in an in vitro intestinal model. We report that this hydrogel can be formed under a moderate environment that is amenable to incorporation of some biologics. The system showed a shear-thinning behavior. AP hydrogel released approximately 60% of the drug within 5 h and showed reasonable a cytotoxicity profile. The study therefore provides evidence that AP hydrogel has potential for local delivery of macromolecules to the intestinal mucosa in IBD.
生物制剂已经改变了炎症性肠病(IBD)的治疗方式,但人们担心注射给药后会出现意外的全身毒性以及治疗反应丧失。直肠给药生物制剂可能会降低治疗成本,同时能更安全、有效地将药物递送至炎症部位。水凝胶有可能成为生物制剂的有效载体,从而改善其向发炎肠黏膜的递送效果。在此,我们制备了一种基于棕榈酸维生素C酯(AP)的水凝胶系统,并将一种模型大分子药物(荧光标记葡聚糖)纳入该系统。对凝胶特性的表征包括流变学、药物负载与释放、细胞毒性以及在体外肠道模型中的药物递送。我们报告称,这种水凝胶可以在适合掺入某些生物制剂的温和环境下形成。该系统呈现出剪切变稀行为。AP水凝胶在5小时内释放了约60%的药物,并且显示出合理的细胞毒性特征。因此,该研究提供了证据,表明AP水凝胶具有将大分子局部递送至IBD肠黏膜的潜力。